| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa | 13 | 2024 | 18 | 2.420 |
Why?
|
| Dermatitis, Atopic | 11 | 2024 | 41 | 2.250 |
Why?
|
| Neurocutaneous Syndromes | 4 | 2024 | 17 | 1.720 |
Why?
|
| Lipomatosis | 2 | 2024 | 16 | 1.440 |
Why?
|
| Ectodermal Dysplasia | 3 | 2024 | 43 | 1.340 |
Why?
|
| Eye Diseases | 3 | 2024 | 113 | 1.040 |
Why?
|
| Eosinophilia | 2 | 2020 | 101 | 1.000 |
Why?
|
| Acne Vulgaris | 6 | 2022 | 19 | 0.930 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 4 | 2022 | 6 | 0.930 |
Why?
|
| Skin Abnormalities | 2 | 2024 | 32 | 0.930 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2024 | 23 | 0.890 |
Why?
|
| Pyrimidinones | 1 | 2024 | 40 | 0.890 |
Why?
|
| Skin | 10 | 2022 | 502 | 0.890 |
Why?
|
| Pyridones | 1 | 2024 | 111 | 0.840 |
Why?
|
| Ichthyosis | 3 | 2024 | 19 | 0.840 |
Why?
|
| Eye Abnormalities | 4 | 2024 | 106 | 0.820 |
Why?
|
| Eczema | 2 | 2022 | 28 | 0.810 |
Why?
|
| Immunosuppressive Agents | 3 | 2024 | 645 | 0.800 |
Why?
|
| Pemphigoid, Bullous | 1 | 2020 | 5 | 0.720 |
Why?
|
| Syringoma | 1 | 2020 | 1 | 0.720 |
Why?
|
| Severity of Illness Index | 15 | 2024 | 2837 | 0.710 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2020 | 15 | 0.700 |
Why?
|
| Exanthema | 1 | 2020 | 68 | 0.660 |
Why?
|
| Skin Neoplasms | 4 | 2024 | 802 | 0.660 |
Why?
|
| Mastocytosis | 1 | 2019 | 7 | 0.650 |
Why?
|
| Skin Diseases | 5 | 2014 | 122 | 0.650 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 53 | 0.640 |
Why?
|
| Molluscum Contagiosum | 2 | 2016 | 11 | 0.600 |
Why?
|
| Hemangioma | 3 | 2017 | 94 | 0.600 |
Why?
|
| Scalp Dermatoses | 1 | 2017 | 5 | 0.590 |
Why?
|
| Patient Care Planning | 1 | 2018 | 122 | 0.570 |
Why?
|
| Humans | 85 | 2025 | 122633 | 0.560 |
Why?
|
| Plectin | 1 | 2016 | 2 | 0.560 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2017 | 93 | 0.550 |
Why?
|
| Propranolol | 1 | 2017 | 128 | 0.550 |
Why?
|
| Consensus | 4 | 2024 | 606 | 0.550 |
Why?
|
| Limb Deformities, Congenital | 1 | 2017 | 105 | 0.540 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 3506 | 0.540 |
Why?
|
| Urologic Diseases | 1 | 2016 | 44 | 0.540 |
Why?
|
| Dermatology | 5 | 2024 | 34 | 0.530 |
Why?
|
| Dermatitis | 2 | 2013 | 25 | 0.510 |
Why?
|
| Sirolimus | 1 | 2017 | 219 | 0.510 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2017 | 234 | 0.510 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 996 | 0.480 |
Why?
|
| Erythema | 3 | 2024 | 24 | 0.460 |
Why?
|
| Dermatologic Agents | 5 | 2025 | 30 | 0.450 |
Why?
|
| Child | 40 | 2025 | 24086 | 0.450 |
Why?
|
| Infant, Newborn | 13 | 2024 | 8064 | 0.440 |
Why?
|
| Rickets | 1 | 2013 | 9 | 0.430 |
Why?
|
| Perineum | 3 | 2014 | 50 | 0.420 |
Why?
|
| Ear Diseases | 1 | 2013 | 18 | 0.420 |
Why?
|
| Ichthyosis, Lamellar | 2 | 2024 | 4 | 0.410 |
Why?
|
| Professional-Family Relations | 1 | 2013 | 95 | 0.410 |
Why?
|
| Caregivers | 4 | 2022 | 563 | 0.400 |
Why?
|
| Parvovirus B19, Human | 1 | 2011 | 30 | 0.390 |
Why?
|
| Physician-Patient Relations | 2 | 2013 | 426 | 0.390 |
Why?
|
| Parvoviridae Infections | 1 | 2011 | 36 | 0.390 |
Why?
|
| Pain, Procedural | 2 | 2023 | 10 | 0.380 |
Why?
|
| Cellulitis | 1 | 2011 | 64 | 0.380 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2013 | 107 | 0.380 |
Why?
|
| Ichthyosiform Erythroderma, Congenital | 2 | 2025 | 3 | 0.370 |
Why?
|
| Infant | 23 | 2025 | 12272 | 0.370 |
Why?
|
| Male | 42 | 2025 | 59714 | 0.360 |
Why?
|
| Patient Participation | 1 | 2013 | 218 | 0.350 |
Why?
|
| Psoriasis | 2 | 2013 | 45 | 0.350 |
Why?
|
| Cicatrix | 2 | 2017 | 125 | 0.350 |
Why?
|
| Body Image | 1 | 2010 | 37 | 0.350 |
Why?
|
| Administration, Topical | 5 | 2024 | 144 | 0.340 |
Why?
|
| Mood Disorders | 1 | 2010 | 123 | 0.330 |
Why?
|
| Communication | 1 | 2013 | 510 | 0.310 |
Why?
|
| Medication Adherence | 1 | 2013 | 385 | 0.310 |
Why?
|
| Argyria | 1 | 2008 | 1 | 0.310 |
Why?
|
| Silver Sulfadiazine | 1 | 2008 | 9 | 0.310 |
Why?
|
| Female | 37 | 2025 | 65117 | 0.310 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2008 | 5 | 0.310 |
Why?
|
| Collodion | 1 | 2008 | 8 | 0.310 |
Why?
|
| Silver | 1 | 2008 | 22 | 0.300 |
Why?
|
| Streptococcus | 1 | 2008 | 61 | 0.300 |
Why?
|
| Child, Preschool | 22 | 2025 | 13794 | 0.290 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 70 | 0.290 |
Why?
|
| Immunoglobulin G | 2 | 2011 | 771 | 0.280 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 1300 | 0.280 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 439 | 0.280 |
Why?
|
| Bacterial Toxins | 1 | 2008 | 176 | 0.280 |
Why?
|
| Diagnosis, Differential | 7 | 2015 | 1864 | 0.270 |
Why?
|
| Staphylococcus aureus | 2 | 2020 | 457 | 0.260 |
Why?
|
| Delphi Technique | 2 | 2024 | 200 | 0.260 |
Why?
|
| Skin Care | 2 | 2020 | 14 | 0.260 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 64 | 0.260 |
Why?
|
| Adolescent | 24 | 2025 | 18987 | 0.250 |
Why?
|
| Dermatomycoses | 1 | 2005 | 15 | 0.250 |
Why?
|
| Nevus | 2 | 2024 | 36 | 0.250 |
Why?
|
| Asthma | 1 | 2013 | 746 | 0.250 |
Why?
|
| Opportunistic Infections | 1 | 2005 | 79 | 0.240 |
Why?
|
| Pruritus | 2 | 2014 | 41 | 0.240 |
Why?
|
| Low-Level Light Therapy | 2 | 2021 | 13 | 0.240 |
Why?
|
| Mutation | 11 | 2018 | 5771 | 0.230 |
Why?
|
| Foot Diseases | 1 | 2004 | 24 | 0.230 |
Why?
|
| Nevus, Sebaceous of Jadassohn | 1 | 2024 | 1 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 3079 | 0.230 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2003 | 14 | 0.230 |
Why?
|
| Hamartoma | 1 | 2004 | 51 | 0.220 |
Why?
|
| Virtual Reality | 1 | 2023 | 27 | 0.220 |
Why?
|
| Failure to Thrive | 1 | 2024 | 90 | 0.220 |
Why?
|
| Immunoglobulin A | 1 | 2024 | 197 | 0.220 |
Why?
|
| Biological Products | 1 | 2025 | 113 | 0.210 |
Why?
|
| Quality of Life | 1 | 2013 | 1921 | 0.210 |
Why?
|
| Skin Diseases, Vascular | 1 | 2022 | 1 | 0.210 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2003 | 141 | 0.210 |
Why?
|
| Telangiectasis | 1 | 2022 | 8 | 0.210 |
Why?
|
| Abnormalities, Multiple | 3 | 2024 | 964 | 0.210 |
Why?
|
| Treatment Outcome | 9 | 2025 | 12055 | 0.200 |
Why?
|
| Transition to Adult Care | 1 | 2024 | 119 | 0.200 |
Why?
|
| Epidermolysis Bullosa Simplex | 1 | 2021 | 1 | 0.200 |
Why?
|
| Epidermolysis Bullosa, Junctional | 1 | 2021 | 2 | 0.200 |
Why?
|
| Skin Cream | 2 | 2019 | 5 | 0.200 |
Why?
|
| Ointments | 2 | 2019 | 14 | 0.200 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2023 | 164 | 0.190 |
Why?
|
| Port-Wine Stain | 1 | 2021 | 6 | 0.190 |
Why?
|
| Sturge-Weber Syndrome | 1 | 2021 | 7 | 0.190 |
Why?
|
| Staphylococcal Infections | 2 | 2020 | 552 | 0.180 |
Why?
|
| Self Care | 2 | 2020 | 210 | 0.170 |
Why?
|
| Detergents | 1 | 2020 | 24 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 5 | 2020 | 2395 | 0.170 |
Why?
|
| Off-Label Use | 1 | 2019 | 25 | 0.170 |
Why?
|
| Wound Healing | 3 | 2017 | 451 | 0.170 |
Why?
|
| Anxiety | 3 | 2023 | 953 | 0.170 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 1148 | 0.170 |
Why?
|
| Cetirizine | 1 | 2019 | 4 | 0.160 |
Why?
|
| Diphenhydramine | 1 | 2019 | 10 | 0.160 |
Why?
|
| Mucous Membrane | 1 | 2019 | 84 | 0.160 |
Why?
|
| Ranitidine | 1 | 2019 | 30 | 0.160 |
Why?
|
| Osteomalacia | 2 | 2013 | 7 | 0.160 |
Why?
|
| Triamcinolone Acetonide | 1 | 2019 | 36 | 0.160 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1067 | 0.160 |
Why?
|
| Iatrogenic Disease | 1 | 2019 | 131 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 501 | 0.160 |
Why?
|
| Mevalonate Kinase Deficiency | 1 | 2018 | 1 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2024 | 621 | 0.150 |
Why?
|
| Connexins | 2 | 2011 | 56 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2018 | 73 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2024 | 749 | 0.150 |
Why?
|
| Isotretinoin | 1 | 2017 | 25 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 419 | 0.140 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 94 | 0.130 |
Why?
|
| Young Adult | 6 | 2025 | 8817 | 0.130 |
Why?
|
| Surveys and Questionnaires | 6 | 2024 | 3648 | 0.130 |
Why?
|
| Skin Ulcer | 2 | 2014 | 32 | 0.130 |
Why?
|
| Age Factors | 4 | 2014 | 2788 | 0.130 |
Why?
|
| Heterozygote | 1 | 2017 | 671 | 0.120 |
Why?
|
| Clinical Competence | 2 | 2024 | 977 | 0.120 |
Why?
|
| Skin Absorption | 2 | 2019 | 6 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 1675 | 0.120 |
Why?
|
| North America | 3 | 2021 | 234 | 0.110 |
Why?
|
| Hypophosphatemia | 1 | 2013 | 9 | 0.110 |
Why?
|
| Nevus, Pigmented | 1 | 2013 | 33 | 0.110 |
Why?
|
| Anal Canal | 1 | 2014 | 80 | 0.110 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2013 | 4 | 0.110 |
Why?
|
| Education, Medical | 1 | 2017 | 285 | 0.110 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 5019 | 0.110 |
Why?
|
| Growth and Development | 1 | 2013 | 22 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1015 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 156 | 0.100 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 142 | 0.100 |
Why?
|
| Rothmund-Thomson Syndrome | 2 | 2003 | 48 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 154 | 0.100 |
Why?
|
| Impetigo | 1 | 2012 | 5 | 0.100 |
Why?
|
| Disinfectants | 1 | 2012 | 25 | 0.100 |
Why?
|
| Adenosine Triphosphatases | 2 | 2003 | 208 | 0.100 |
Why?
|
| Palatal Neoplasms | 1 | 2011 | 5 | 0.100 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2014 | 220 | 0.100 |
Why?
|
| DNA Helicases | 2 | 2003 | 225 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2013 | 309 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2011 | 210 | 0.090 |
Why?
|
| Prognosis | 2 | 2019 | 4488 | 0.090 |
Why?
|
| Disease Management | 1 | 2015 | 514 | 0.090 |
Why?
|
| Administration, Cutaneous | 2 | 2008 | 60 | 0.090 |
Why?
|
| Simplexvirus | 1 | 2011 | 99 | 0.090 |
Why?
|
| Sebaceous Glands | 1 | 2010 | 4 | 0.090 |
Why?
|
| Propionibacterium acnes | 1 | 2010 | 12 | 0.090 |
Why?
|
| Keratosis | 1 | 2010 | 16 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2011 | 57 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1248 | 0.090 |
Why?
|
| Retinoids | 3 | 2020 | 33 | 0.090 |
Why?
|
| Liver | 1 | 2017 | 1725 | 0.090 |
Why?
|
| Adult | 9 | 2025 | 28881 | 0.090 |
Why?
|
| Mosaicism | 2 | 2009 | 240 | 0.090 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2010 | 75 | 0.080 |
Why?
|
| Hypopigmentation | 1 | 2009 | 11 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2025 | 15916 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2009 | 50 | 0.080 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2011 | 154 | 0.080 |
Why?
|
| Puberty, Precocious | 1 | 2009 | 27 | 0.080 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 359 | 0.080 |
Why?
|
| Canada | 2 | 2020 | 294 | 0.080 |
Why?
|
| Bandages | 2 | 2019 | 56 | 0.080 |
Why?
|
| Risk Assessment | 5 | 2019 | 3316 | 0.080 |
Why?
|
| Aneuploidy | 1 | 2009 | 152 | 0.080 |
Why?
|
| Aminoquinolines | 1 | 2008 | 35 | 0.070 |
Why?
|
| Biopsy | 1 | 2011 | 1238 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 729 | 0.070 |
Why?
|
| Ectodermal Dysplasia 1, Anhidrotic | 1 | 2007 | 1 | 0.070 |
Why?
|
| Capillaries | 1 | 2007 | 66 | 0.070 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2011 | 141 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2010 | 465 | 0.070 |
Why?
|
| Fetal Diseases | 1 | 2011 | 439 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2024 | 1380 | 0.070 |
Why?
|
| Incontinentia Pigmenti | 1 | 2006 | 16 | 0.070 |
Why?
|
| Diseases in Twins | 1 | 2007 | 92 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2821 | 0.070 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 442 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 651 | 0.070 |
Why?
|
| Prevalence | 3 | 2021 | 2388 | 0.070 |
Why?
|
| Etanercept | 1 | 2006 | 39 | 0.060 |
Why?
|
| Parents | 1 | 2013 | 1017 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1523 | 0.060 |
Why?
|
| Angiomatosis | 1 | 2005 | 6 | 0.060 |
Why?
|
| Biopsy, Needle | 3 | 2019 | 230 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 1683 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2011 | 1132 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2019 | 286 | 0.060 |
Why?
|
| Netherton Syndrome | 1 | 2025 | 2 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 2008 | 244 | 0.060 |
Why?
|
| Photosensitivity Disorders | 1 | 2004 | 10 | 0.060 |
Why?
|
| DNA | 2 | 2008 | 1591 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2004 | 42 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2020 | 1162 | 0.060 |
Why?
|
| Age Distribution | 2 | 2019 | 404 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1584 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2009 | 695 | 0.060 |
Why?
|
| Trichotillomania | 1 | 2004 | 34 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2019 | 234 | 0.060 |
Why?
|
| Recurrence | 1 | 2008 | 1418 | 0.060 |
Why?
|
| Triazoles | 1 | 2004 | 138 | 0.060 |
Why?
|
| Pemphigus | 1 | 2003 | 5 | 0.050 |
Why?
|
| Hypertrichosis | 1 | 2003 | 5 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 229 | 0.050 |
Why?
|
| Amebicides | 1 | 2003 | 1 | 0.050 |
Why?
|
| Acanthamoeba | 1 | 2003 | 9 | 0.050 |
Why?
|
| Collagen Diseases | 1 | 2003 | 3 | 0.050 |
Why?
|
| Amebiasis | 1 | 2003 | 10 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2019 | 1466 | 0.050 |
Why?
|
| Disease Progression | 3 | 2019 | 2024 | 0.050 |
Why?
|
| Hair Follicle | 1 | 2003 | 33 | 0.050 |
Why?
|
| Epidermis | 1 | 2003 | 60 | 0.050 |
Why?
|
| Hair Removal | 1 | 2003 | 7 | 0.050 |
Why?
|
| Observer Variation | 1 | 2024 | 300 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 1684 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2003 | 321 | 0.050 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2003 | 138 | 0.050 |
Why?
|
| Cadherins | 1 | 2003 | 163 | 0.050 |
Why?
|
| Gastrostomy | 1 | 2022 | 84 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2019 | 6012 | 0.050 |
Why?
|
| Pain Management | 1 | 2023 | 171 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2022 | 102 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 270 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2004 | 374 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 335 | 0.050 |
Why?
|
| Texas | 2 | 2024 | 3541 | 0.050 |
Why?
|
| Lasers, Dye | 1 | 2021 | 1 | 0.050 |
Why?
|
| United States | 3 | 2024 | 10559 | 0.050 |
Why?
|
| Vitamin D Deficiency | 1 | 2002 | 70 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2002 | 115 | 0.050 |
Why?
|
| Mupirocin | 1 | 2020 | 19 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 462 | 0.050 |
Why?
|
| Enteral Nutrition | 1 | 2022 | 248 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1390 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2003 | 257 | 0.040 |
Why?
|
| Pain | 1 | 2023 | 468 | 0.040 |
Why?
|
| Cosmetics | 1 | 2020 | 4 | 0.040 |
Why?
|
| Cholestasis | 1 | 2002 | 148 | 0.040 |
Why?
|
| Pediatrics | 1 | 2009 | 1137 | 0.040 |
Why?
|
| Puberty | 2 | 2010 | 94 | 0.040 |
Why?
|
| Middle Aged | 4 | 2020 | 25849 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 639 | 0.040 |
Why?
|
| Risk Factors | 3 | 2009 | 9943 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2003 | 845 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2019 | 19 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2019 | 65 | 0.040 |
Why?
|
| Drug Approval | 1 | 2019 | 39 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 266 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 426 | 0.040 |
Why?
|
| Incidence | 3 | 2019 | 3040 | 0.040 |
Why?
|
| Immunoglobulin D | 1 | 2018 | 6 | 0.040 |
Why?
|
| Connexin 26 | 2 | 2011 | 13 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 527 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3341 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 500 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2018 | 49 | 0.040 |
Why?
|
| Fear | 1 | 2019 | 201 | 0.040 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2017 | 45 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2011 | 357 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 117 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 362 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1730 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1915 | 0.030 |
Why?
|
| Syndrome | 2 | 2009 | 1111 | 0.030 |
Why?
|
| Oils | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2019 | 4686 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2013 | 1758 | 0.030 |
Why?
|
| Nails | 1 | 2013 | 17 | 0.030 |
Why?
|
| Scalp | 1 | 2013 | 54 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 858 | 0.030 |
Why?
|
| RecQ Helicases | 2 | 2003 | 62 | 0.030 |
Why?
|
| Pedigree | 2 | 2007 | 1579 | 0.020 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 20 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1583 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 397 | 0.020 |
Why?
|
| Facial Neoplasms | 1 | 2009 | 19 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 253 | 0.020 |
Why?
|
| Eye | 1 | 2011 | 226 | 0.020 |
Why?
|
| Sternum | 1 | 2009 | 53 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 611 | 0.020 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2009 | 50 | 0.020 |
Why?
|
| Exome | 1 | 2013 | 1041 | 0.020 |
Why?
|
| Interferon Inducers | 1 | 2008 | 6 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 670 | 0.020 |
Why?
|
| Aortic Coarctation | 1 | 2009 | 105 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 157 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2009 | 208 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 3870 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 319 | 0.020 |
Why?
|
| Twins, Dizygotic | 1 | 2007 | 38 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 6188 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 309 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2017 | 1158 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 169 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1240 | 0.020 |
Why?
|
| Tooth Abnormalities | 1 | 2006 | 9 | 0.020 |
Why?
|
| Leg | 1 | 2007 | 154 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2007 | 190 | 0.020 |
Why?
|
| Karyotyping | 1 | 2006 | 330 | 0.020 |
Why?
|
| Eosinophils | 1 | 2006 | 121 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 262 | 0.020 |
Why?
|
| Craniofacial Abnormalities | 1 | 2007 | 243 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 815 | 0.020 |
Why?
|
| Voriconazole | 1 | 2004 | 35 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2004 | 19 | 0.010 |
Why?
|
| Nervous System Malformations | 1 | 2006 | 127 | 0.010 |
Why?
|
| Gels | 1 | 2004 | 60 | 0.010 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2004 | 65 | 0.010 |
Why?
|
| Sex Factors | 1 | 2008 | 1242 | 0.010 |
Why?
|
| Desmogleins | 1 | 2003 | 1 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 419 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 208 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2003 | 213 | 0.010 |
Why?
|
| Ear | 1 | 2003 | 25 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 1398 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2003 | 63 | 0.010 |
Why?
|
| Registries | 1 | 2009 | 1379 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 391 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2005 | 379 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2003 | 381 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 129 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 462 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 2004 | 293 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 2002 | 77 | 0.010 |
Why?
|
| Introns | 1 | 2002 | 302 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 793 | 0.010 |
Why?
|
| RNA Splicing | 1 | 2002 | 223 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 1065 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 1068 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1293 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 1594 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 7105 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2002 | 1164 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 2942 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 3093 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2009 | 1801 | 0.010 |
Why?
|
| Animals | 3 | 2003 | 33618 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 2017 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 18982 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 2935 | 0.010 |
Why?
|
| Mice | 2 | 2003 | 17430 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2003 | 3710 | 0.010 |
Why?
|
| Phenotype | 1 | 2003 | 4200 | 0.010 |
Why?
|